Thrombosis and von Willebrand Factor - PubMed (original) (raw)
Review
Thrombosis and von Willebrand Factor
Minoo Shahidi. Adv Exp Med Biol. 2017.
Abstract
One of the key players in both hemostasis and thrombosis is von Willebrand factor (vWF), which demonstrates a duality between these two processes. Thrombus is structured by numerous elements, including endothelial cells, platelets, plasma proteins and shear stress alteration. In circulation, once a vessel wall is injured, collagen is exposed and platelets attach to the site of injury. Accordingly, vWF mediates adherence of platelets to the damaged vessel wall by binding both to the collagen and platelet receptor. A growing body of data also indicates a role for neutrophil extracellular traps (NETs) in human thrombosis as scaffolds for vWF, promoting thrombosis. VWF also mediates the protection of factor VIII, a main cofactor of the intrinsic clotting pathway. Since vWF plays a critical role in both thrombotic and bleeding events, a decreased plasma level of this factor may point to a bleeding disorder, while an elevated plasma level may predict occurrence of thrombosis. Since thrombotic events are the foremost cause of death, inhibiting the vWF activity would be a novel prophylaxis to reduce these events. Though, accumulated data have made vWF a promising focus for research on cardiovascular diseases (CVD). This chapter, however, aims to clarify the role of vWF in thrombus formation and pathogenesis of thrombosis.
Keywords: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13); Endothelial cell; Neutrophil extracellular traps (NETs); Platelet; Shear stress; Thrombosis; Thrombotic thrombocytopenic purpura (TTP); Von Willebrand factor.
Similar articles
- Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Abdelgawwad MS, Cao W, Zheng L, Kocher NK, Williams LA, Zheng XL. Abdelgawwad MS, et al. Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2731-2743. doi: 10.1161/ATVBAHA.118.311407. Arterioscler Thromb Vasc Biol. 2018. PMID: 30354235 Free PMC article. - Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
Dhanesha N, Prakash P, Doddapattar P, Khanna I, Pollpeter MJ, Nayak MK, Staber JM, Chauhan AK. Dhanesha N, et al. Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1829-37. doi: 10.1161/ATVBAHA.116.307660. Epub 2016 Jul 21. Arterioscler Thromb Vasc Biol. 2016. PMID: 27444201 Free PMC article. - Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C. Tersteeg C, et al. Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21. Circulation. 2014. PMID: 24449821 - Function of von Willebrand factor in haemostasis and thrombosis.
Reininger AJ. Reininger AJ. Haemophilia. 2008 Nov;14 Suppl 5:11-26. doi: 10.1111/j.1365-2516.2008.01848.x. Haemophilia. 2008. PMID: 18786007 Review. - Von Willebrand factor: another janus-faced hemostasis protein.
Franchini M, Mannucci PM. Franchini M, et al. Semin Thromb Hemost. 2008 Oct;34(7):663-9. doi: 10.1055/s-0028-1104545. Epub 2008 Dec 15. Semin Thromb Hemost. 2008. PMID: 19085767 Review.
Cited by
- Advances in the development of hemostatic biomaterials for medical application.
Sung YK, Lee DR, Chung DJ. Sung YK, et al. Biomater Res. 2021 Nov 12;25(1):37. doi: 10.1186/s40824-021-00239-1. Biomater Res. 2021. PMID: 34772454 Free PMC article. Review. - Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells.
Qu Y, Dunn ZS, Chen X, MacMullan M, Cinay G, Wang HY, Liu J, Hu F, Wang P. Qu Y, et al. Hum Gene Ther. 2022 Mar;33(5-6):223-236. doi: 10.1089/hum.2021.050. Epub 2021 Aug 25. Hum Gene Ther. 2022. PMID: 34225478 Free PMC article. - An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2.
Silver AB, Tzeng SY, Lager M, Wang J, Ishihara J, Green JJ, Spangler JB. Silver AB, et al. Cell Rep Med. 2023 Nov 21;4(11):101289. doi: 10.1016/j.xcrm.2023.101289. Cell Rep Med. 2023. PMID: 37992685 Free PMC article. - Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia.
Geronikolou SA, Takan I, Pavlopoulou A, Mantzourani M, Chrousos GP. Geronikolou SA, et al. Int J Mol Med. 2022 Mar;49(3):35. doi: 10.3892/ijmm.2022.5090. Epub 2022 Jan 21. Int J Mol Med. 2022. PMID: 35059730 Free PMC article. - The Versatility of Opportunistic Infections Caused by Gemella Isolates Is Supported by the Carriage of Virulence Factors From Multiple Origins.
García López E, Martín-Galiano AJ. García López E, et al. Front Microbiol. 2020 Mar 31;11:524. doi: 10.3389/fmicb.2020.00524. eCollection 2020. Front Microbiol. 2020. PMID: 32296407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous